ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in Salt Lake City, UT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Endometrial Cancer
Non-Small-Cell Lung Carcinoma
Ovarian Cancer

Triple Negative Breast Cancer trials near Salt Lake City, UT, USA:

Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer (ELEVATE TNBC)

or paclitaxel (cohort 1) or with sacituzumab govitecan-hziy (cohort 2) in patients with non-surgically removable locally advanced or metastatic triple...

Active, not recruiting
Triple-Negative Breast Cancer
Drug: Sacituzumab Govitecan-hziy
Drug: Magrolimab

Phase 2

Gilead Sciences
Gilead Sciences

Salt Lake City, Utah, United States and 44 other locations

oral immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells through selective inhibition of phosphoin ...

Active, not recruiting
Breast Cancer
Renal Cell Carcinoma
Drug: nab-paclitaxel
Drug: Bevacizumab

Phase 2

Infinity Pharmaceuticals
Infinity Pharmaceuticals

Salt Lake City, Utah, United States and 23 other locations

escalation will be open to the enrollment of patients diagnosed with triple-negative breast cancer or ovarian cancer...

Enrolling
Metastatic Breast Cancer
Recurrent Ovarian Carcinoma
Drug: Belinostat
Drug: Ribociclib

Phase 1

Utah System of Higher Education (USHE)
Utah System of Higher Education (USHE)

Salt Lake City, Utah, United States and 1 other location

or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after su...

Enrolling
Triple Negative Breast Cancer
Drug: Capecitabine
Drug: Sacituzumab govitecan-hziy (SG)

Phase 3

Gilead Sciences
Gilead Sciences

Salt Lake City, Utah, United States and 160 other locations

Locations recently updated

with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors...

Active, not recruiting
Triple Negative Breast Cancer
PD-L1 Positive
Drug: Pembrolizumab
Drug: Carboplatin

Phase 3

Gilead Sciences
Gilead Sciences

Salt Lake City, Utah, United States and 505 other locations

This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors....

Enrolling
Triple Negative Breast Cancer, TNBC
Small Cell Lung Cancer, SCLC
Drug: JAB-2485 (Aurora A inhibitor)

Phase 1, Phase 2

Jacobio Pharmaceuticals

Salt Lake City, Utah, United States and 4 other locations

This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It wi ...

Enrolling
Ovarian Neoplasms
Gastric Cancer
Drug: pembrolizumab
Drug: PF-08046054

Phase 1

Seagen
Seagen

West Valley City, Utah, United States and 23 other locations

and antitumor activity of PRO1107 in patients with advanced solid tumors. This study consists of 2 parts, Part A: dose escalation and dose l...

Enrolling
Endometrial Cancer
Non-small Cell Lung Cancer
Drug: PRO1107

Phase 1, Phase 2

Genmab
Genmab

Salt Lake City, Utah, United States and 3 other locations

This study will test the safety, including side effects, and determine the characteristics of a drug called PRO1184 in participants with solid tumors...

Enrolling
Hormone Receptor-positive/Her2 Negative Breast Cancer
High Grade Serous Ovarian Cancer
Drug: PRO1184 intravenous infusion of PRO1184
Drug: PRO1184

Phase 1, Phase 2

Genmab
Genmab

West Valley City, Utah, United States of America and 31 other locations

preliminary antitumor activity of NKT3447 in adult subjects with cyclin E1 (CCNE1) amplified ovarian cancer at the RDEs selected in Dose Es...

Enrolling
Solid Tumor
Ovarian Neoplasms
Drug: NKT3447

Phase 1

NiKang Therapeutics

West Valley City, Utah, United States of America and 7 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems